EGFR mutations in non-small cell lung cancer

EGFR is a receptor tyrosine kinase on chromosome 7p11.2. Activating mutations cluster in the kinase domain (exons 18–21), making the receptor constitutively active independent of ligand binding. The result is sustained downstream signaling through RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, driving cellular proliferation, survival, and migration.

Different mutation classes produce structurally distinct active-state conformations. L858R and exon 19 deletions destabilize the inactive conformation, exposing the ATP-binding pocket. Exon 20 insertions push the C-helix into a constitutively active position that classical EGFR TKIs cannot effectively engage. This structural difference is why drug selection by mutation class matters more than picking from a single "EGFR inhibitor" menu.

EGFR mutations are among the most common actionable alterations in non-small cell lung cancer. Prevalence varies sharply with ancestry, smoking history, and histology. East Asian non-smoker adenocarcinoma populations show prevalence near 50%; US and EU cohorts run ~15%. Squamous histology shows EGFR mutation rates closer to 5%, and small-cell lung cancer rarely carries actionable EGFR alterations.

Adenocarcinoma without smoking history in any ancestry deserves comprehensive EGFR testing including liquid biopsy if tissue is insufficient. Detection at progression also matters: T790M emerges in roughly 50–60% of patients progressing on first or second-generation TKIs and remains relevant when prior osimertinib was not used.

Comprehensive EGFR testing for newly diagnosed advanced NSCLC should include exons 18–21. Liquid biopsy is appropriate when tissue is insufficient. The following are FDA-approved companion diagnostics in EGFR-mutant NSCLC:

Liquid biopsy alone has lower sensitivity than tissue, particularly for low tumor burden disease. A negative liquid result does not rule out an EGFR mutation; reflex to tissue when the clinical pretest probability is high.

At progression on first-line osimertinib, repeat tissue or liquid biopsy is appropriate to identify the dominant resistance mechanism. Common findings include:

• MET amplification (~15%) — combination strategies under investigation.
• EGFR C797S (~7%) — fourth-generation EGFR TKIs in trials; cis vs trans T790M configuration matters.
• HER2 amplification, RET fusion, BRAF V600E, KRAS G12C emergence — bypass pathways.
• Histologic transformation to small-cell lung cancer (~3–10%) — biopsy can be diagnostic.
• Off-target / unknown — substantial fraction; clinical trial enrollment is reasonable.

The MARIPOSA-2 study demonstrated activity for amivantamab + chemotherapy after osimertinib progression. Trial referral for novel agents (4th-gen EGFR TKIs, MET-EGFR combinations, antibody-drug conjugates) is reasonable when resistance mechanism is identified.

• TP53 co-mutation: common; generally does not alter targeted-therapy selection but worsens prognosis.
• RB1 + TP53 co-loss: increases risk of small-cell transformation.
• MET amplification at diagnosis: rare but informs whether MET-targeted combinations are considered earlier.
• STK11 / KEAP1 co-mutation: less common in EGFR-mutant tumors than in KRAS-mutant tumors but worth noting if found.

ClinicalTrials.gov is the source of truth for active studies; recruiting status changes daily. Useful filters for EGFR-mutant NSCLC:

• NCT04988295 (MARIPOSA-2) — post-osimertinib progression.
• Search "EGFR exon 20 insertion lung cancer recruiting" for next-generation exon 20-active TKIs.
• Search "C797S EGFR lung cancer recruiting" for fourth-generation EGFR TKIs.
• Search "antibody drug conjugate EGFR NSCLC recruiting" for ADC programs (e.g., patritumab deruxtecan).

Osimertinib is metabolized primarily by CYP3A4. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) can substantially reduce osimertinib exposure; consider alternatives or close monitoring. Strong CYP3A4 inhibitors require attention to QT-interval prolongation. There is no CPIC Level A guideline for osimertinib at the time of writing (2026-05).

Amivantamab carries infusion-related reaction risk (most common with first dose); the subcutaneous formulation reduces but does not eliminate this. Premedication is standard. No pharmacogenomic dose-adjustment guideline applies.

• CIViC EID3017 — EGFR L858R + osimertinib (Tier I-A).
• ClinVar — EGFR variant pathogenicity classifications.
• ClinicalTrials.gov NCT04988295 (MARIPOSA-2).
• PubMed 29151374 — Soria et al., FLAURA, NEJM 2018.
• PubMed 32955177 — Wu et al., ADAURA, NEJM 2020.
• PubMed 37937763 — Zhou et al., PAPILLON, NEJM 2023.
• AMP/ASCO/CAP 2017 — Li MM et al., J Mol Diagn 2017;19(1):4-23.
• openFDA labels for osimertinib (Tagrisso), amivantamab (Rybrevant).

• This is a decision-support reference, not a CAP/CLIA-validated diagnostic. Do not paste into a sign-out report without lab-director review.
• Drug labels and trial-recruiting status change. Verify the current openFDA label and ClinicalTrials.gov entry at decision time.
• EGFR-mutant NSCLC management evolves quickly. This page is reviewed quarterly; check the "Last updated" date in the header.
• Companion diagnostic selection often depends on local availability and turnaround time. F1CDx, cobas, and Guardant360 CDx are not interchangeable across all clinical scenarios.

What is the first-line treatment for EGFR L858R or exon 19 deletion NSCLC?

Osimertinib monotherapy is the standard first-line targeted therapy, based on the FLAURA trial. It is FDA-approved with FoundationOne CDx, cobas EGFR Mutation Test v2, and Guardant360 CDx as companion diagnostics. Osimertinib also covers T790M, simplifying sequencing.

Can osimertinib be used first-line for EGFR exon 20 insertions?

No. Exon 20 insertions respond poorly to osimertinib and other classical EGFR TKIs. The FDA-approved first-line for unresectable advanced exon 20 insertion NSCLC is amivantamab plus chemotherapy (PAPILLON).

Why are PD-1 inhibitors not used as monotherapy in EGFR-mutant NSCLC?

Multiple trials have shown poor response to single-agent PD-1 / PD-L1 inhibitors in EGFR-mutant NSCLC across PD-L1 expression subgroups. Standard targeted therapy with osimertinib remains first-line for activating EGFR mutations.

What companion diagnostics are FDA-approved for osimertinib?

FoundationOne CDx (tissue), cobas EGFR Mutation Test v2 (tissue and plasma), and Guardant360 CDx (plasma) are FDA-approved companion diagnostics for osimertinib.